Objective To systematically evaluate the clinical effectiveness of Baduanjin for patients with non-small cell lung cancer. Methods The databases, PubMed, EMBASE (Ovid), The Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Weipu, Wanfang, and CBM were searched for the randomized controlled trials (RCTs) on Baduanjin (or combined with other treatments) in the treatment of patients with non-small cell lung cancer from their establishment to July 26, 2022. Meta analysis was performed using the Stata 17 software. The risk of bias was assessed according to the Cochrane's Handbook for systematic reviewers' risk of bias criteria for literature quality assessment. The outcome measures were pulmonary function tests (FEV1 and FVC), Borg dyspnea score, 6-min walk test, Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and Functional Assessment of Lung Cancer Therapy (FACT-L) (version 4.0). Results Six RCTs with a total of 322 patients were included. Meta analysis showed that the test group had better FEV1 [SMD= 0.53, 95%CI (0.13, 0.94), P=0.01], FVC [SMD=0.58, 95%CI (0.17, 0.98), P=0.005], 6-min walk test [SMD=0.56, 95%CI (0.34, 0.79), P<0.01], and SAS score [SMD=-1.18, 95%CI (-1.51,-0.85), P<0.01] than the control group. The test group had significantly greater improvement in the Borg dyspnea score [SMD=-0.32, 95%CI (-0.72, 0.07), P=0.11], SDS [SMD=-0.62, 95%CI (-1.68, 0.44), P=0.253], and scores of physical status [SMD=0.35,95%CI(-0.44,1.13),P=0.385], social and family status [SMD=0.44, 95%CI (-0.29, 1.17), P=0.242], affective status [SMD=0.36, 95%CI (-0.31, 1.04), P=0.293], and additional concern [SMD=0.43, 95%CI (-0.41, 1.27), P=0.313] and total score [SMD=1.22, 95%CI (-0.18, 2.63), P=0.088] of FACT-L (version 4.0) than the control group, with statistical differences. Conclusions Baduanjin is able to improve the patients' lung function, exercise tolerance, and anxiety status; its effects on dyspnea, depression status as well as improvement on the functional assessment scale for lung cancer treatment are not significant, so it needs further study.